A Study To Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of ASP2408 After Multiple Dose Subcutaneous Injections in Patients With Rheumatoid Arthritis on Methotrexate

NCT ID: NCT02052375

Last Updated: 2014-02-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-06-30
• Study Completion Date: 2013-12-31

Brief Summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of two dosing regimens of multiple, subcutaneous (sc) injections of ASP2408 in patients with Rheumatoid Arthritis (RA) on Methotrexate (MTX) and to evaluate the pharmacodynamics (PD) of ASP2408.

Detailed Description

This is an ascending dose frequency study. There are two cohorts of active and placebo patients. The first cohort is dosed every 4 weeks for a total of 3 doses. The second cohort is dosed every two weeks for a total of 3 doses.

Conditions

Rheumatoid Arthritis; Pharmacokinetics of ASP2408

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Blinding Strategy: QUADRUPLE

Study Groups

ASP2408 low dosing frequency

Group Type: EXPERIMENTAL

ASP2408

Intervention Type: DRUG

subcutaneous injection

ASP2408 high dosing frequency

Group Type: EXPERIMENTAL

ASP2408

Intervention Type: DRUG

subcutaneous injection

Placebo low dosing frequency

Group Type: EXPERIMENTAL

Placebo

Intervention Type: DRUG

subcutaneous injection

Placebo high dosing frequency

Group Type: EXPERIMENTAL

Placebo

Intervention Type: DRUG

subcutaneous injection

Interventions

ASP2408

subcutaneous injection

Intervention Type: DRUG

Placebo

subcutaneous injection

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Subject weighs at least 50 kg.
• Subject has a body mass index (BMI) of ≤ 35 kg/m2.
• Subject's 12-lead electrocardiogram (ECG) results are normal at Screening and Day 1 prior to study drug dosing or, if abnormal, the abnormality is not clinically significant as determined by the Investigator.
• Subject has Rheumatoid Arthritis (RA) that was diagnosed according to the 1987 revised criteria of the American College of Rheumatology (ACR) ≥ 6 months prior to Screening.
• Subject meets the ACR 1991 revised criteria for Global Functional Status in RA, Class I, II or III at Screening.
• Subject MUST be on concomitant methotrexate (MTX):

• for ≥ 3 months prior to Day 1, AND
• at a stable dose (10 - 25 mg/week) for ≥ 28 days prior to Day 1 and throughout the study.
• Subject's other related medications taken for the treatment of RA at the time of Screening must meet the noted stability requirements and remain on a stable regimen, as follows:

• Non-steroidal anti-inflammatory drugs (NSAIDs), selective cyclooxy-genase-2 (COX-2) inhibitors, oral corticosteroids (≤ 10 mg of prednisone, or equivalent, daily) or low dose opioids (≤ 30 mg of oral morphine, or equivalent, daily) must be stable for ≥ 28 days prior to Screening and remain so throughout the Treatment and Observation Period.
• Hydroxychloroquine (Plaquenil®) and sulfasalazine must have started ≥ 2 months, and be stable for ≥ 28 days, prior to Day 1.

Exclusion Criteria

• Subject has an ongoing infection or has had an infection requiring intravenous antibiotics within 1 month prior to Day 1.
• Subject has a past history of serious opportunistic infection.
• Subject has a positive Mantoux tuberculin skin or QuantiFERON-TB Gold test within 90 days of, or at Screening, and has not completed an adequate course of antimicrobial therapy per CDC guidelines.
• Subject received any live or live-attenuated vaccine within 30 days prior to Day 1.
• Subject received any of the following:

• Anakinra (Kineret®), etanercept (Enbrel®), or adalimumab (Humira®) within 60 days prior to Day 1.
• Rituximab (Rituxan®) or any other anti-CD20 antibody within 180 days prior to Day 1.
• Leflunomide (Arava®) within 60 days prior to drug dosing on Day 1, unless the subject has undergone cholestyramine washout at least 30 days prior to Day 1.
• Oral or injectable gold, azathioprine, penicillamine, cyclosporine, or tacrolimus within 30 days prior to Day 1.
• Cyclophosphamide within 180 days prior to Day 1.
• Subject has received any CTLA4-Ig molecule (including, but not limited to abatacept [Orencia®] and belatacept [Nulojix]).
• Subject has participated in a previous clinical study with treatment with ASP2408 or ASP2409 or has participated in another dose cohort of the current trial.
• Subject has previously participated in any interventional clinical study, or has received an experimental agent within 56 days or 5 half-lives, whichever is longer, prior to Day 1.
• Subject has a history of prolonged QT syndrome.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Astellas Pharma Global Development, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Senior Medical Director

Role: STUDY_DIRECTOR

Astellas Pharma Global Development, Inc.

Locations

Pinnacle Research Group, LLC

Anniston, Alabama, United States

Altoona Center for Clinical Research

Duncansville, Pennsylvania, United States

Metroplex Clinical Research Center, LLC

Dallas, Texas, United States

Countries

United States

Other Identifiers

2408-CL-0201

Identifier Type: -

Identifier Source: org_study_id